Two LNP formulations for siRNA delivery, Patisiran (Onpattro) and Givosiran (Givlaari), have been approved for the treatment of transthyretin‐mediated amyloidosis (in 2018) and acute hepatic porphyria (in 2019), respectively.[16, 30] More recently, the developments achieved in the field of nanoparticles have resulted in several LNP formulations being evaluated in clinical trials for solid tumor gene therapy including the delivery of antisense nucleic acids (WGI‐0301), plasmid DNA (Reqorsa), siRNA (TKM‐080301), miRNA (INT‐1B3), and mRNA (OTX‐2002), as listed in Table 1. Here, TTR is linked to amyloidosis.